NEWGEN BIOPHARMA CORP. (OTCMKTS:NEWG) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrants Certifying Accountant.
(a) Resignation of Independent Certifying Accountant
Effective February 15, 2017, KLJ Associates, LLP (KLJ) resigned
as the independent registered public accounting firm of NewGen
BioPharma Corp., a Nevada corporation (the Company). KLJs
resignation was not the result of any disagreement between the
Company and KLJ on matters of accounting principles or practices,
financial statement disclosure or auditing scope or procedures.
The resignation of KLJ as our independent registered public
accounting firm was accepted and approved by our Board of
Directors by written consent on February 16, 2017.
The reports of KLJ regarding the Companys financial statements
for the fiscal years ended October 31, 2016 and 2015 did not
contain any adverse opinion or disclaimer of opinion, and were
not qualified or modified as to uncertainty, audit scope or
accounting principles, except that KLJs audit report on the
Companys financial statements for the fiscal years ended October
31, 2016 and 2015 contained an explanatory paragraph noting there
was substantial doubt about the Companys ability to continue as a
going concern.
During the years ended October 31, 2016 and 2015, and during the
period from November 1, 2016 to February 15, 2017, the date of
KLJs resignation, (i) there were no disagreements with KLJ on any
matter of accounting principles or practices, financial statement
disclosure or auditing scope or procedures, which disagreements,
if not resolved to the satisfaction of KLJ, would have caused KLJ
to make reference to such disagreement in its reports; and (ii)
there were no reportable events as defined in Item 304(a)(1)(v)
of Regulation S-K.
The Company has provided KLJ with a copy of the foregoing
disclosures and requested that KLJ furnish the Company with a
letter addressed to the SEC stating whether or not it agrees with
the above statements. A copy of such letter is filed as Exhibit
16.1 to this Current Report on Form 8-K.
(b) Engagement of Independent Certifying Accountant
On February 16, 2017, our Board of Directors engaged Michael T.
Studer CPA P.C. (MTS) as the independent registered public
accounting firm to review the Companys financial statements for
the fiscal quarter ending January 31, 2017.
During each of the Companys two most recent fiscal years and
through the interim periods preceding the engagement of MTS, the
Company (a) has not engaged MTS as either the principal
accountant to audit the Companys financial statements, or as an
independent accountant to audit a significant subsidiary of the
Company and on whom the principal accountant is expected to
express reliance in its report; and (b) has not consulted with
MTS regarding (i) the application of accounting principles to a
specific transaction, either completed or proposed, or the type
of audit opinion that might be rendered on the Companys financial
statements, and no written report or oral advice was provided to
the Company by MTS concluding there was an important factor to be
considered by the Company in reaching a decision as to an
accounting, auditing or financial reporting issue; or (ii) any
matter that was either the subject of a disagreement, as that
term is defined in Item 304(a)(1)(iv) of Regulation S-K, or a
reportable event, as that term is described in Item 304(a)(1)(v)
of Regulation S-K, relating to the Company.
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
Description |
|
16.1 |
Letter of KLJ Associates, LLP. |
|
|
About NEWGEN BIOPHARMA CORP. (OTCMKTS:NEWG)
NewGen BioPharma Corp., formerly Greenwind NRG Inc., is a development-stage company. The Company intends to operate in the business of off the grid wind power systems for residential, cabin, recreational vehicle (RV), boat and shop use. The Company will provide an opportunity for customers to research and purchase off-the-grid wind turbines capable of producing energy for use in residential homes and elsewhere. Its focus market will be Ireland. It intends to purchase turbines and sell them to retail consumers throughout Ireland and to expand throughout North America. The Company seeks to focus on users seeking an alternative, renewable source of energy for a range of uses. Its products will have a rated wind speed of approximately 20 miles per hour. Its over two larger turbines will have the ability to generate approximately five kilowatts per hour. The Company intends to generate revenues by selling and offering installation and maintenance services of off-the-grid wind turbines. NEWGEN BIOPHARMA CORP. (OTCMKTS:NEWG) Recent Trading Information
NEWGEN BIOPHARMA CORP. (OTCMKTS:NEWG) closed its last trading session 00.00 at 1.68 with 500 shares trading hands.